Philippe JEAN-PIERRE

---

• Type de publi. :
• Date de publi. : 03/10/2022
• Auteurs : Nicolas BalasJean-Philippe Denis
• Organismes : Montpellier Research in Management Université Paris Dauphine-PSL Université Paris-Saclay Réseaux Innovation Territoires et Mondialisation

---

Résumé : Xerfi Canal a reçu Nicolas Balas pour parler de l'apport de Bourdieu dans le management. Une interview menée par Jean-Philippe Denis.

---

Fichiers liés : Pierre_Bourdieu_auteur_subversif_du_management_Nicolas_Balas_.mp4

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 03/10/2022
• Auteurs : Tobias GaussJustin RichardsCostanza TortùFrançois-Xavier AgeronSophie HamadaJulie JosseFrançois HussonAnatole HarroisThomas ScaleaValentin VivantEric MeaudreJonathan MorrisonSamue GalvagnoPierre BouzatFrançois AlbasiniOlivier BriotLaurent ChaboudSophie Chateigner CoelschAlexandre ChaumatThomas ComlarOlivier DebasGuillaume DebatyEmmanuelle Dupré-NaletSamuel GayEdouard GinestieEdouard GirardJules GrèzeMarc HaesevoetsMarie HallainEtienne HallerChristophe HoareauBernard LanaspreSafia LespinasseAlbrice LevratRomain Mermillod-BlondinPhilippe NicoudElisabeth RancurelJean-Marc ThouretClaire VallenetCécile VallotBénédicte ZerrPaér-Sélim AbbackGérard AudibertMathieu BoutonnetThomas ClavierFabrice CookMohamed EljamriThierry FlochElisabeth GaertnerDelphine GarrigueThomas GeeraertsSebastien GetteAnne GodierPierre GossetJean-Luc HanouzJean-Denis MoyerOlivier LangeronMarc LeoneJulien PottecherJonathan PortazMathieu RauxMarion ScottoMathieu WilligAlexia Hardy
• Organismes : Hôpital Beaujon [AP-HP] Hôpital d'Annecy Centre de recherche en épidémiologie et santé des populations Institut Desbrest d'Epidémiologie et de Santé Publique Médecine de précision par intégration de données et inférence causale Institut de Recherche Mathématique de Rennes Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Université Paris-Saclay Hôpital d'Instruction des Armées Sainte Anne École du Val de Grâce Centre Hospitalier Universitaire [CHU Grenoble] [GIN] Grenoble Institut des Neurosciences Hopital Saint-Jean-de-Maurienne
• Publié dans JAMA Network Open le 29/10/2020

---

Résumé : Importance Hemorrhagic shock is a common cause of preventable death after injury. Vasopressor administration for patients with blunt trauma and hemorrhagic shock is often discouraged. Objective To evaluate the association of early norepinephrine administration with 24-hour mortality among patients with blunt trauma and hemorrhagic shock. Design, Setting, and Participants This retrospective, multicenter, observational cohort study used data from 3 registries in the US and France on all consecutive patients with blunt trauma from January 1, 2013, to December 31, 2018. Patients were alive on admission with hemorrhagic shock, defined by prehospital or admission systolic blood pressure less than 100 mm Hg and evidence of hemorrhage (ie, prehospital or resuscitation room transfusion of packed red blood cells, receipt of emergency treatment for hemorrhage control, transfusion of >10 units of packed red blood cells in the first 24 hours, or death from hemorrhage). Blunt trauma was defined as any exposure to nonpenetrating kinetic energy, collision, or deceleration. Statistical analysis was performed from January 15, 2021, to February 22, 2022. Exposure Continuous administration of norepinephrine in the prehospital environment or resuscitation room prior to hemorrhage control, according to European guidelines. Main Outcomes and Measures The primary outcome was 24-hour mortality, and the secondary outcome was in-hospital mortality. The average treatment effect (ATE) of early norepinephrine administration on 24-hour mortality was estimated according to the Rubin causal model. Inverse propensity score weighting and the doubly robust approach with 5 distinct analytical strategies were used to determine the ATE. Results A total of 52 568 patients were screened for inclusion, and 2164 patients (1508 men [70%]; mean [SD] age, 46 [19] years; median Injury Severity Score, 29 [IQR, 17-36]) presented with acute hemorrhage and were included. A total of 1497 patients (69.1%) required emergency hemorrhage control, 128 (5.9%) received a prehospital transfusion of packed red blood cells, and 543 (25.0%) received a massive transfusion. Norepinephrine was administered to 1498 patients (69.2%). The 24-hour mortality rate was 17.8% (385 of 2164), and the in-hospital mortality rate was 35.6% (770 of 2164). None of the 5 analytical strategies suggested any statistically significant association between norepinephrine administration and 24-hour mortality, with ATEs ranging from –4.6 (95% CI, –11.9 to 2.7) to 2.1 (95% CI, –2.1 to 6.3), or between norepinephrine administration and in-hospital mortality, with ATEs ranging from –1.3 (95% CI, –9.5 to 6.9) to 5.3 (95% CI, –2.1 to 12.8). Conclusions and Relevance The findings of this study suggest that early norepinephrine infusion was not associated with 24-hour or in-hospital mortality among patients with blunt trauma and hemorrhagic shock. Randomized clinical trials that study the effect of early norepinephrine administration among patients with trauma and hypotension are warranted to further assess whether norepinephrine is safe for patients with hemorrhagic shock.

---

Fichiers liés : gauss_2022_oi_220977_1664506622.06301.pdf

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 03/10/2022
• Auteurs : Martin DentanGianluca BorgeseJean-Luc AutranDaniela MunteanuMoindjie SoilihiPhilippe MoreauFrancis-Pierre PellissierBenjamin SantraineJérôme BucalossiPhilippe RocheVictor MalherbeMatteo CecchettoGarcía Alía Rubén
• Organismes : ITER organization ITER organization Institut des Matériaux, de Microélectronique et des Nanosciences de Provence Institut des Matériaux, de Microélectronique et des Nanosciences de Provence Institut des Matériaux, de Microélectronique et des Nanosciences de Provence CEA Cadarache CEA Cadarache CEA Cadarache CEA Cadarache STMicroelectronics [Crolles] STMicroelectronics [Crolles] CERN [Genève] CERN [Genève]

---

Résumé : We validated a method for predicting the Soft Error Rate (SER) in the WEST tokamak operated with deuterium plasmas, and we applied it to predict the SER in the ITER tokamak operated with deuterium-tritium plasmas.

---

Fichiers liés : Radecs_2022_HAL.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 03/10/2022
• Auteurs : Francois GouinEberhard StoeckleCharles HonoréMickael RoparsMehrdad JafariJean Camille MatteiAlexandre RochwergerSébastien CarrereDenis WaastGwenaël FerronJean-Christophe MachiavelloPhilippe AnractFrédéric MarchalFrançois SirveauxOren MarcoJérôme GuiramandBrice PaquetteAntonio Di MarcoSylvain CauseretJean-Marc GuilloitPauline SoibinetDimitri TzanisPierre GimberguesFabrice FiorenzaFranck DujardinLouis Le NailJean-Christophe RuzicClaire Chemin-AiriauMagali MorellePierre MeeusMarie KaranianFrançois Le LoarerGualter VazJean-Yves Blay
• Organismes : Centre Léon Bérard [Lyon] Institut Bergonié [Bordeaux] Institut Gustave Roussy Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] Hôpital Privé Clairval [Marseille] Aix Marseille Université Marseille medical genetics - Centre de génétique médicale de Marseille Hôpital de la Conception [CHU - APHM] Marseille medical genetics - Centre de génétique médicale de Marseille Hôpital de la Conception [CHU - APHM] Institut de Recherche en Cancérologie de Montpellier Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire de Toulouse Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] Hôpital Cochin [AP-HP] Centre de Recherche en Automatique de Nancy Centre Hospitalier Régional Universitaire de Nancy Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris] Institut Paoli-Calmettes Centre Hospitalier Régional Universitaire de Besançon Centre Hospitalier Universitaire [Strasbourg] Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] Centre Régional de Lutte contre le Cancer François Baclesse [Caen] Institut Jean Godinot [Reims] Institut Curie [Paris] Centre Jean Perrin [Clermont-Ferrand] CHU Limoges Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen CHU Trousseau [APHP] CHU Saint-Pierre Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Institut Bergonié [Bordeaux] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Université Claude Bernard Lyon 1 UNICANCER
• Publié dans BMC Cancer le 01/11/2020

---

Résumé : Background: This French nationwide NETSARC exhaustive prospective cohort aims to explore the impact of systematic re-excision (RE) as adjuvant care on overall survival (OS), local recurrence free survival (LRFS), and local and distant control (RFS) in patients with soft tissue sarcoma (STS) with positive microscopic margins (R1) after initial resection performed outside of a reference center. Methods: Eligible patients had experienced STS surgery outside a reference center from 2010 to 2017, and had R1 margins after initial surgery. Characteristics and treatment comparisons used chi-square for categorical variables and Kruskall-Wallis test for continuous data. Survival distributions were compared in patients reexcised (RE) or not (No-RE) using a log-rank test. A Cox proportional hazard model was used for subgroup analysis. Results: A total of 1,284 patients had experienced initial STS surgery outside NETSARC with R1 margins, including 1,029 patients with second operation documented. Among the latter, 698 patients experienced re-excision, and 331 were not re-excised. Characteristics were significantly different regarding patient age, tumor site, tumor size, tumor depth, and histotype in the population of patients re-excised (RE) or not (No-RE). The study identified RE as an independent favorable factor for OS (HR 0.36, 95%CI 0.23-0.56, p<0.0001), for LRFS (HR 0.45, 95%CI 0.36-0.56, p<0.0001), and for RFS (HR 0.35, 95%CI 0.26-0.46, p<0.0001). Conclusion: This large nationwide series shows that RE improved overall survival in patients with STS of extremities and trunk wall, with prior R1 resection performed outside of a reference center. RE as part of adjuvant care should be systematically considered.

---

Fichiers liés : s12885-022-10121-5.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 03/10/2022
• Auteurs : David SulmanMichel ZeitouniJohanne SilvainMathieu KerneïsPaul GuedeneyOlivier BarthélémyDelphine BrugierPierre SabouretBenoît LattucaEmilie MertensJulianne PossonNiki ProcopiTomy SalloumJean-Philippe ColletGilles Montalescot
• Organismes : Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Groupe Action CHU Pitié-Salpêtrière [AP-HP] Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Groupe Action CHU Pitié-Salpêtrière [AP-HP] Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Groupe Action CHU Pitié-Salpêtrière [AP-HP] Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Groupe Action CHU Pitié-Salpêtrière [AP-HP] Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Groupe Action CHU Pitié-Salpêtrière [AP-HP] Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Groupe Action CHU Pitié-Salpêtrière [AP-HP] Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Groupe Action CHU Pitié-Salpêtrière [AP-HP] Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Groupe Action CHU Pitié-Salpêtrière [AP-HP] Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Groupe Action CHU Pitié-Salpêtrière [AP-HP] Initial MAnagement and prevention of acute orGan failures IN critically ill patiEnts Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Groupe Action CHU Pitié-Salpêtrière [AP-HP] Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Groupe Action CHU Pitié-Salpêtrière [AP-HP] Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Groupe Action CHU Pitié-Salpêtrière [AP-HP] Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Groupe Action CHU Pitié-Salpêtrière [AP-HP] Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Groupe Action CHU Pitié-Salpêtrière [AP-HP] CHU Pitié-Salpêtrière [AP-HP] Groupe Action Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases
• Publié dans European Heart Journal - Cardiovascular Pharmacotherapy le 31/10/2019

---

Résumé : Aims: The European Society of Cardiology (ESC) has released three consecutive guidelines within 5 years addressing cardiovascular prevention, risk scores, and cholesterol treatment. This study aims to evaluate whether the 2021 ESC guidelines improved the eligibility of individuals for primary prevention statin therapy before their first ST-segment elevation myocardial infarction (STEMI), and for intensive lipid-lowering treatments in secondary prevention. Methods and results: The cardiovascular risk category of 2757 consecutive individuals admitted for a first STEMI was evaluated to assess whether they would have been eligible for primary prevention statins according to 2021 vs. 2019 and 2016 ESC guidelines. Eligibility for intensive lipid-lowering therapy in secondary prevention was assessed according to the real-life follow-up low-density lipoprotein cholesterol (LDL-C) and the expected follow-up LDL-C. More individuals would have been eligible for primary prevention statins according to 2021 and 2019 vs. 2016 guidelines (61.8% vs. 38.7% vs. 23.6%, P < 0.01), a finding observed in both men (62.3% vs. 35.0% vs. 24.9%, P < 0.01) and women (60.2% vs. 50.7% vs. 19.3%, P = 0.18). Only 27% of individuals reached the LDL-C objective of 55 mg/L in secondary prevention: using the ESC stepwise approach, 61.7% were eligible for higher doses of statins, 26.2% for ezetimibe, and 12.1% for a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor (PCSK9i). Based on expected LDL-C reductions, eligibility for a PCSK9i in secondary prevention was greater with 2021 vs. 2016 guidelines (44.5% vs. 22.5%, P < 0.01). Conclusion: The 2021 ESC guidelines improved the detection and treatment of individuals at risk for a first myocardial infarction. In secondary prevention, 70% of patients kept LDL-C levels above 55 mg/dL: increasing the statin dose and adding ezetimibe were the most frequently recommended therapeutic actions.

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 02/10/2022
• Auteurs : Jean FurstossPierre HirelPhilippe CarrezPatrick Cordier
• Organismes : Unité Matériaux et Transformations - UMR 8207 Unité Matériaux et Transformations - UMR 8207 Unité Matériaux et Transformations - UMR 8207 Unité Matériaux et Transformations - UMR 8207

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2022
• Auteurs : Jean-Philip BrugalPhilippe FosseJean-Baptiste FourvelPierre MagniezAudrey RousselA. UzunidisPatricia Valensi
• Organismes : Laboratoire méditerranéen de préhistoire Europe-Afrique Laboratoire méditerranéen de préhistoire Europe-Afrique Gestion des ressources naturelles , environnements et sociétés Culture et Environnements, Préhistoire, Antiquité, Moyen-Age Université Côte d'Azur Instituto Internacional de Investigaciones Prehistóricas de Cantrabria [Santander] Laboratoire méditerranéen de préhistoire Europe-Afrique
• Publié dans Bulletin du Musée d'Anthropologie préhistorique de Monaco le 27/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2022
• Auteurs : Florence Laigle-DonadeyPhilippe MetellusJacques GuyotatPhilippe MeneiFrançois ProustHenry DufourOlivier ChinotJérôme HonnoratThierry FaillotPhilippe PaquisPhilippe PeruzziEvelyne EmeryJean-Sébastien GuillamoAlexandre CarpentierMichel WagerSaid LebbahDavid HajageJean-Yves DelattrePhilippe Cornu
• Organismes : CHU Pitié-Salpêtrière [AP-HP] CHU Pitié-Salpêtrière [AP-HP] Hôpital Privé Clairval [Marseille] Hospices Civils de Lyon Centre Hospitalier Universitaire d'Angers Hôpital Charles Nicolle [Rouen] Institut Marseille Maladies Rares Hôpital de la Timone [CHU - APHM] Institut NeuroMyoGène Hospices Civils de Lyon Hôpital Beaujon [AP-HP] Département de Neurochirurgie [Hôpital Pasteur de Nice] Service de neurologie [Reims] Service de Neurochirurgie [CHU Caen] CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie CHU Pitié-Salpêtrière [AP-HP] Sorbonne Université Centre hospitalier universitaire de Poitiers = Poitiers University Hospital CHU Pitié-Salpêtrière [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Pitié-Salpêtrière [AP-HP] CHU Pitié-Salpêtrière [AP-HP] CHU Pitié-Salpêtrière [AP-HP]
• Publié dans Journal of Neurosurgery le 26/10/2020

---

Résumé : OBJECTIVE The role of surgery in the treatment of malignant gliomas in the elderly is not settled. The authors conducted a randomized trial that compared tumor resection with biopsy only—both followed by standard therapy—in such patients. METHODS Patients ≥ 70 years of age with a Karnofsky Performance Scale (KPS) score ≥ 50 and presenting with a radiological suspicion of operable glioblastoma (GBM) were randomly assigned between tumor resection and biopsy groups. Subsequently, they underwent standard radiotherapy during the first years of the trial (2008–2017), with the addition of adjunct therapy with temozolomide when this regimen became standard (2017–2019). The primary endpoint was survival, and secondary endpoints were progression-free survival (PFS), cognitive status (Mini-Mental State Examination), autonomy (KPS), quality of life (European Organisation for Research and Treatment of Cancer [EORTC] QLQ-C30 and QLQ-BN20), and perioperative morbidity and mortality. RESULTS Between 2008 and 2019, 107 patients from 9 centers were enrolled in the study; 101 were evaluable for analysis because a GBM was histologically confirmed (50 in the surgery arm and 51 in the biopsy arm). There was no statistically significant difference in median survival between the surgery (9.37 months) and the biopsy (8.96 months, p = 0.36) arms (adjusted HR 0.79, 95% CI 0.52–1.21, p = 0.28). However, the surgery group had an increased PFS (5.06 vs 4.02 months; p = 0.034) (adjusted HR 0.50, 95% CI 0.32–0.78, p = 0.002). Less deterioration of quality of life and KPS score evolution than in the biopsy group was observed. Surgery was not associated with increased mortality or morbidity. CONCLUSIONS This study suggests that debulking surgery is safe, and, compared to biopsy, is associated with a less severe deterioration of QOL and autonomy and, a significant although modest improvement of PFS in elderly patients suffering from newly diagnosed malignant glioma. Although resection does not provide a significant survival benefit in the elderly, we believe that the risk/benefit analysis favors an attempt at optimal tumor resection in this population, providing careful preoperative geriatric evaluation.

---

Fichiers liés : Laigle-Donadey CSA MANUSCRIPT REVISED 01 08 2022 VF_modif acceptees.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2022
• Auteurs : Madjid MorsliAgathe BoudetQuentin KerharoRobin StephanFlorian SalipanteCatherine Dunyach-RemyLinda HouhamdiPierre-Edouard FournierJean-Philippe LavigneMichel Drancourt
• Organismes : Microbes Evolution Phylogénie et Infections Hôpital Universitaire de Réadaptation, de Rééducation et d'Addictologie du CHU de Nîmes [Grau-du-Roi] Virulence Bactérienne et Infections Chroniques Institut Hospitalier Universitaire Méditerranée Infection Centre Hospitalier Universitaire de Nîmes BIO-RAD Hôpital Universitaire Carémeau [Nîmes] Virulence Bactérienne et Infections Chroniques Centre Hospitalier Universitaire de Nîmes Institut Hospitalier Universitaire Méditerranée Infection Institut Hospitalier Universitaire Méditerranée Infection Vecteurs - Infections tropicales et méditerranéennes Centre Hospitalier Universitaire de Nîmes Virulence Bactérienne et Infections Chroniques Institut Hospitalier Universitaire Méditerranée Infection Microbes Evolution Phylogénie et Infections
• Publié dans EBioMedicine le 28/10/2020

---

Résumé : Background: Point-Of-Care (POC) diagnosis of life-threatening community-acquired meningitis currently relies on multiplexed RT-PCR assays, that lack genotyping and antibiotic susceptibility profiling. We assessed the usefulness of real-time metagenomics (RTM) directly applied to the cerebrospinal fluid (CSF) for the identification, typing and susceptibility profiling of pathogens responsible for community-acquired meningitis. Methods: A series of 52 CSF samples from patients suspected of having community-acquired meningitis, were investigated at POC by direct RTM in parallel to routine real-time multiplex PCR (RT-PCR) and bacterial culture, for the detection of pathogens. RTM-generated sequences were blasted in real-time against an in-house database incorporating the panel of 12 most prevalent pathogens and against NCBI using EPI2ME online software, for pathogen identification. In-silico antibiogram and genotype prediction were determined using the ResFinder bio-tool and MLST online software. Findings: Over eight months, routine multiplex RT-PCR yielded 49/52 positive CSFs, including 21 Streptococcus pneumoniae, nine Neisseria meningitidis, eight Haemophilus influenzae, three Streptococcus agalactiae, three Herpesvirus-1, two Listeria monocytogenes, and one each of Escherichia coli, Staphylococcus aureus and Varicella-Zoster Virus. Parallel RTM agreed with the results of 47/52 CSFs and revealed two discordant multiplex RT-PCR false positives, one H. influenzae and one S. pneumoniae. Both multiplex RT-PCR and RTM agreed on the negativity of three CSFs. While multiplex RT-PCR routinely took 90 min, RTM took 120 min, although the pipeline analysis detected the pathogen genome after 20 min of sequencing in 33 CSF samples; and after two hours in 14 additional CSFs; yielding> 50% genome coverage in 19 CSFs. RTM identified 14 pathogen genotypes, including a majority of H. influenzae b, N. meningitidis B and S. pneumoniae 11A and 3A. In all 16 susceptible cultured bacteria, the in-silico antibiogram agreed with the in-vitro antibiogram in 10 cases, available within 48 h in routine bacteriology. Interpretation: In addition to pathogen detection, RTM applied to CSF samples offered supplementary information on bacterial profiling and genotyping. These data provide the proof-of-concept that RTM could be implemented in a POC laboratory for one-shot diagnostic and genomic surveillance of pathogens responsible for life-threatening meningitis.

---

Fichiers liés : 1-s2.0-S2352396422004297-main.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/10/2022
• Auteurs : Pierre-Alexandre LeziartThomas CorbèresThomas FlayolsSteve TonneauNicolas MansardPhilippe Souères
• Organismes : Équipe Mouvement des Systèmes Anthropomorphes The University of Edinburgh Équipe Mouvement des Systèmes Anthropomorphes The University of Edinburgh Équipe Mouvement des Systèmes Anthropomorphes Équipe Mouvement des Systèmes Anthropomorphes
• Publié dans IEEE Robotics and Automation Letters le 02/11/2020

---

Résumé : This paper presents significant improvements to the nominal control architecture of the open-access Solo-12 quadruped that were done to implement and compare different centroidal Model Predictive Controllers (MPC). This work was motivated by our previous study in which various MPC schemes of increasing complexity were tested in simulation. They range from a simplified linearized model with contact points fixed by a heuristic, to a nonlinear one that also optimizes the contact points locations. We describe the developments that were necessary to implement such control schemes on the real robot while doubling its maximum velocity. Notably, to synthesize a stable whole-body controller, the inverse dynamics resolution was replaced by a mixed inverse kinematics and quadratic programming scheme. These developments enabled the successful deployments of the various centroidal MPCs on Solo-12. Experimental results show that all MPCs lead to quite similar performances with the proposed whole-body controller and, as a consequence, do not confirm the result of previous simulation study that concluded on the preeminence of the nonlinear centroidal MPC optimizing both the center of mass trajectory and the foot placements.

---

Fichiers liés : leziart2022_Improved_Control_Scheme_Solo_Quadruped.pdf

---

Source